Solascren
৳ 360.00
Solascren
Description
Indication
Sunblock, Solar urticaria, Acute solar dermatitis, Acute lupus erythematosus, Herpes simplex, Polymorphic light eruption, Cutaneous albinism, Vitiligo, Drug-induced photosensitivity
Adult Dose
Apply 45 minutes before swimming or sweat producing exercise. A single application may give day-long protection but the product should be re-applied during prolonged periods of sunning and after swimming or excessive sweating.
Contraindication
The drug is contraindicated in individuals with a history of sensitivity reactions to any of the components of the preparation.
Mode of Action
Oxybenzone Although benzophenones are primarily UV-B absorbers, oxybenzone absorbs well through UV-A II. Oxybenzone can be considered a broad-spectrum absorber. It significantly augments UV-B protection when used in a given formula. Avobenzone Often referred to by its trade name, Parsol 1789, butyl methoxydibenzoylmethane or avobenzone provides superior protection through a large portion of the UV-A range, including UV-A I. A significant addition to sunscreen products for true broad-spectrum UV protection, concerns have been raised regarding its photostability and its potential to degrade other sunscreen ingredients in products in which it is used. Titanium dioxide The ideal sunscreen agent would be chemically inert, safe, and absorb or reflect through the full UV spectrum. Titanium dioxide meets these criteria limited only by aesthetics. By decreasing the particle size of this pigment to microsize or ultrafine grades, thereby making it less visible on the skin surface, some of these advantages could be used. This ingredient can be classified as a broad-spectrum agent. Padimate O Padimate O is the most potent UV-B absorber.
Precaution
Application to broken skin should be avoided. Contact with the eyes and other mucous membranes should be avoided.
Side Effect
Signs of irritations (including erythema, burning or rash) may appear when applied to sensitive or broken skin.
Reviews
There are no reviews yet.